Adenom der Hypophyse
Deterministische Ansicht der Quelle YAML Entität. Klinische Autorität bleibt mit den zitierten Quell-IDs und Rezensenten Sign-off Zustand.
| ID | DIS-PITUITARY-ADENOMA |
|---|---|
| Art | Erkrankung |
| Aliase | Kortikotrophes AdenomMEN1-assoziiertes HypophyseadenomNonfunctioning pituitary adenomaPitNETHirntumor der neuroendokrinen HautProlaktinomSomatotroph AdenomАденома гіпофіза |
| Status | reviewed 2026-05-18 | pending_clinical_signoff |
| Erkrankungen | None declared |
| Quellen | SRC-NCCN-CNS-2025 SRC-NCCN-NET-2025 |
Informational support. All recommendations must be verified by a qualified oncologist. Engineering checks are not clinical validation or treatment approval.
| icd_o_3_morphology | 8272/0 |
|---|---|
| icd_o_3_topography | ["C75.1"] |
| icd_10 | D35.2 |
| who_classification | WHO Endokrine und Neuroendokrine Tumore 5 ed (2022) + ZNS 5 end (2021): Klassifikation auf der Grundlage der Linie des pituitären Neuroendocrinen Tumors (PitNET) — Lactotroph / Somatotroph/Corticotroph / Thyrotroph / Gonadotroph / null-Zell |
Anmerkungen
Functional adenomas classified by lineage / hormone hypersecretion; treatment is endocrine-cohort-specific: prolactinoma — dopamine agonists (cabergoline > bromocriptine) first-line, surgery for resistant / intolerant; somatotroph (acromegaly) — transsphenoidal surgery first-line, somatostatin analogs (octreotide LAR, lanreotide, pasireotide LAR), GH-receptor antagonist (pegvisomant) for residual; corticotroph (Cushing disease) — surgery, pasireotide, ketoconazole / metyrapone / osilodrostat for cortisol control; nonfunctioning — surgery for mass effect / visual compromise. MEN1 carriers: cascade screening from age 5 (prolactin + IGF-1 + serum Ca + intact PTH + fasting gastrin + pituitary MRI per protocol).
Verwendet von
Algorithmen
ALGO-MEN1-CARRIER-SURVEILLANCE- ALGO-MEN1-CARRIER-SURVEILLANCEALGO-PITUITARY-ADENOMA-1L- ALGO-PITUITARY-ADENOMA-1L
Erkrankung
DIS-PARATHYROID-CARCINOMA- NebenschilddrüsenkarzinomDIS-PITUITARY-BLASTOMA- Hypophysisches Blastom
Arzneimittel
DRUG-CABERGOLINE- CabergolineDRUG-PASIREOTIDE- Pasireotide
Anwendungsgebiet
IND-PITUITARY-ADENOMA-1L-ACROMEGALY-SURGERY-SSA- IND-PITUITARY-ADENOMA-1L-ACROMEGALY-SURGERY-SSAIND-PITUITARY-ADENOMA-1L-CUSHING-SURGERY-MEDICAL- IND-PITUITARY-ADENOMA-1L-CUSHING-SURGERY-MEDICALIND-PITUITARY-ADENOMA-1L-NFPA-SURGERY-MASS-EFFECT- IND-PITUITARY-ADENOMA-1L-NFPA-SURGERY-MASS-EFFECTIND-PITUITARY-ADENOMA-1L-PROLACTINOMA-CABERGOLINE- IND-PITUITARY-ADENOMA-1L-PROLACTINOMA-CABERGOLINE
Warnhinweis
RF-PITUITARY-MASS-EFFECT-VISUAL-COMPROMISE- Pituitary adenoma (typically nonfunctioning macroadenoma) causing compressive mass effect...
Therapieschema
REG-CABERGOLINE-PROLACTINOMA- Cabergoline für Prolaktinom (Dopaminagonist, First-Line)REG-PASIREOTIDE-CUSHING- Pasireotide bei Cushing-Erkrankungen (Pituitär-gerichtete medizinische Therapie)REG-SSA-ACROMEGALY- Somatostatinanalog für Akromegalie (lanreotide erste Generation SSA; pasireotide für SS...